查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1405987

細胞/基因療法 CDMO 市場規模、佔有率和趨勢分析報告：按階段、產品類型、適應症、地區和細分市場預測，2024-2030 年

Cell And Gene Therapy CDMO Market Size, Share & Trends Analysis Report By Phase, By Product Type, By Indication, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 195 Pages | 商品交期: 2-10個工作天內

價格

細胞和基因治療 CDMO 市場成長和趨勢：

Grand View Research, Inc.最新報告預測，到2030年，全球細胞和基因治療CDMO市場規模預計將達到274.5億美元，2024年至2030年複合年成長率為27.9%。

進行細胞和基因治療領域的研發活動、更加重視解決罕見疾病、擴大創新產品管線、該領域對外包服務的需求不斷成長以及開發過程中的持續技術進步。這些因素導致了細胞和基因治療領域的不斷成長。市場需求。

此外，私營和公共部門增加用於開發新型細胞和基因治療藥物的投資和資金也是支持市場成長的關鍵因素。細胞和基因治療市場投資和融資的一些著名例子包括：

  • 2021年8月，專門從事基因編輯診斷的公司SeQure Dx宣布獲得1750萬美元A輪資金籌措，用於開發基因治療藥物。本輪資金籌措由 Mass General Brigham Ventures 和 RiverVest Venture Partners主導，Casdin Capital、Digitalis Ventures、KdT Ventures、Alexandria Venture Investments 和 Bold Capital Partners 跟投。
  • 2021年8月，專注於眼科疾病非病毒基因治療的臨床階段生物技術公司Eyevensys在B+輪資金籌措中獲得1,200萬美元。

COVID-19 大流行的早期階段對市場產生了負面影響。臨床試驗活動的整體放緩很大程度上是由於對參與者和工作人員安全的擔憂，從而導致了延誤和暫時中止。供應鏈管理（特別是運輸和物流）的中斷帶來了挑戰，而圍繞大流行的不確定性導致需求預測和可行性規劃整體缺乏。然而，透過適應新常態、增強供應鏈彈性以及實施安全措施以應對疫情挑戰，市場已出現反彈。此外，主要企業採取的併購策略有助於在 2021 年之前減輕疫情的負面影響。

細胞/基因療法 CDMO 市場報告亮點

  • 到2023年，臨床前領域將佔最大佔有率，達到66.2%。細胞和基因療法藥物的不斷成長是支持該領域成長的關鍵因素之一。
  • 以產品類型來看，細胞治療領域佔比最大，2023年為41.6%。細胞治療服務對於再生醫學和個人化醫療的進步至關重要。
  • 預計罕見疾病在分析期間的複合年成長率最高為 28.4%。幾種罕見疾病的盛行率不斷上升，導致細胞和基因治療研發活動激增，支持了該領域的發展。
  • 亞太地區預計在預測期內複合年成長率為 29.0%。該地區的顯著成長主要歸因於幾個亞洲經濟體較低的人事費用和營運成本，從而實現了具有成本效益的細胞和基因產品製造。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第 3 章 細胞和基因治療 CDMO 市場變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場抑制因素分析
  • 細胞與基因治療的 CDMO 市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • COVID-19感染疾病的影響分析

第 4 章 細胞/基因治療 CDMO 市場：階段估計與趨勢分析

  • 細胞和基因療法 CDMO 市場（按階段）：細分儀表板
  • 細胞/基因療法 CDMO 市場（依階段）：波動分析
    • 臨床前
    • 臨床

第5章細胞/基因治療 CDMO 市場：產品類型估計和趨勢分析

  • 按產品類型分類的細胞和基因療法 CDMO 市場：細分儀表板
  • 按產品類型分類的細胞/基因療法 CDMO 市場：變異分析
    • 基因治療
    • 基因改造細胞療法
    • 細胞療法

第6章 細胞/基因治療 CDMO 市場：適應症估計與趨勢分析

  • 細胞和基因療法 CDMO 市場，按適應症分類：細分儀表板
  • 細胞和基因治療的 CDMO 市場，按適應症分類：變異分析
    • 瘤
    • 感染疾病
    • 神經系統疾病
    • 罕見疾病
    • 其他

第7章細胞/基因治療 CDMO 市場：區域估計和趨勢分析

  • 2023 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場概述
  • 北美洲
    • 2018-2030 年市場估計與預測
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 印度
    • 中國
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章競爭形勢

  • 市場參與企業分類
    • 創新者
    • 市場領導者
    • 新興玩家
    • 2023 年公司市場佔有率分析
  • 公司簡介
    • Lonza
    • Catalent, Inc
    • Cytiva
    • Samsung Biologics
    • Thermo Fisher Scientific Inc.
    • Novartis AG
    • WuXi AppTec
    • AGC Biologics
    • OmniaBio
    • Rentschler Biopharma SE
    • Charles River Laboratories
Product Code: GVR-4-68040-167-4

Cell And Gene Therapy CDMO Market Growth & Trends:

The global cell and gene therapy CDMO market size is expected to reach USD 27.45 billion by 2030 and is projected to grow at a CAGR of 27.9% from 2024 to 2030, according to a new report by Grand View Research, Inc.Growing research and development activities in cell and gene therapies, heightened focus on addressing rare diseases, the expanding pipeline of innovative products, a rising need for outsourced services in this field, and continuous technological advancements in the development processes are few of the factors collectively contribute to rising demand for the market.

Furthermore, increasing investments and funding from private and public sectors to develop novel cell and gene therapeutics is another significant factor supporting the market growth. A few of the notable examples of investments and funding in the cell and gene therapy market are mentioned below:

  • In August 2021 SeQure Dx, a company specializing in gene editing diagnostics, announced a series A funding round of USD 17.5 million to develop gene therapeutics. This funding was led by Mass General Brigham Ventures and RiverVest Venture Partners, along with Casdin Capital, Digitalis Ventures, KdT Ventures, Alexandria Venture Investments, and Bold Capital Partners
  • In August 2021, Eyevensys, a clinical-stage biotechnology company focusing on nonviral gene therapies for ophthalmic diseases, secured USD 12 million in a series B plus funding round

The initial phase of the COVID-19 pandemic adversely affected the market. The slowdown in overall clinical trial activity was a significant factor, primarily due to concerns about the safety of participants and staff, leading to delays and temporary suspensions. The disruption in supply chain management, particularly in transportation and logistics, posed challenges, and the uncertainty surrounding the pandemic created a general lack of demand forecast and feasibility planning. However, the market recovered through a combination of adapting to new norms, enhancing the resilience of supply chains, and implementing safety measures to navigate the challenges posed by the pandemic. Moreover, mergers and acquisition strategies adopted by the major companies have helped mitigate the negative impact of the pandemic by 2021.

Cell And Gene Therapy CDMO Market Report Highlights:

  • The pre-clinical segment accounted for the largest share of 66.2% in 2023. The increasing pipeline of cell and gene therapeutics is one of the major factors supporting the segment's growth
  • Based on the product type, the cell therapy segment accounted for the largest share of 41.6% in 2023. Cell therapy services are vital in advancing regenerative medicine & personalized medicine
  • Rare diseases are anticipated to witness the highest CAGR of 28.4% across the analysis period. The growing prevalence of several rare diseases has led to a surge in R&D activities in cell and gene therapies, thus supporting segmental growth
  • Asia Pacific is anticipated to witness the highest CAGR of 29.0% during the forecast time frame. The region's substantial growth is primarily attributed to the cost-effective manufacturing of cell and gene products due to lower labor and operational costs in several Asian economies

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Segment Definitions
    • 1.1.2. Phase
    • 1.1.3. Product Type
    • 1.1.4. Indication
  • 1.2. Regional Scope
  • 1.3. Estimates And Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information Or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
    • 1.9.2. Parent Market Analysis
  • 1.10. List Of Secondary Sources
  • 1.11. List Of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Cell and Gene Therapy CDMO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Growing pipeline of cell and gene therapy products to boost the market growth
      • 3.2.1.2. Increasing investments and R&D funding for the development of cell and gene therapeutics
      • 3.2.1.3. Technological innovations across the cell & gene therapy development process
      • 3.2.1.4. Increasing mergers & acquisitions in the cell and gene therapy industry
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Compliance with strict regulatory requirements
      • 3.2.2.2. High development costs of CGT products
  • 3.3. Cell and Gene Therapy CDMO Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat Of New Entrant
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Cell and Gene Therapy CDMO Market: Phase Estimates & Trend Analysis

  • 4.1. Cell and Gene Therapy CDMO Market, By Phase: Segment Dashboard
  • 4.2. Cell and Gene Therapy CDMO Market, By Phase: Movement Analysis
  • 4.3. Cell and Gene Therapy CDMO Market Estimates & Forecasts, By Phase, 2018 - 2030
    • 4.3.1. Pre-clinical
      • 4.3.1.1. Pre-clinical Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million)
    • 4.3.2. Clinical
      • 4.3.2.1. Clinical Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million)

Chapter 5. Cell and Gene Therapy CDMO Market: Product Type Estimates & Trend Analysis

  • 5.1. Cell and Gene Therapy CDMO Market, By Product Type: Segment Dashboard
  • 5.2. Cell and Gene Therapy CDMO Market, By Product Type: Movement Analysis
  • 5.3. Cell and Gene Therapy CDMO Market Estimates & Forecasts, By Product Type, 2018 - 2030
    • 5.3.1. Gene Therapy
      • 5.3.1.1. Gene Therapy Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million)
      • 5.3.1.2. Ex-vivo
      • 5.3.1.2.1. Ex-vivo Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million)
      • 5.3.1.3. In-vivo
      • 5.3.1.3.1. In-vivo Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million)
    • 5.3.2. Gene-Modified Cell Therapy
      • 5.3.2.1. Gene-Modified Cell Therapy Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million)
      • 5.3.2.2. CAR T-cell therapies
      • 5.3.2.2.1. CAR T-cell therapies Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million)
      • 5.3.2.3. CAR-NK cell therapy
      • 5.3.2.3.1. CAR-NK cell therapy Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million)
      • 5.3.2.4. TCR-T cell therapy
      • 5.3.2.4.1. TCR-T cell therapy Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million)
      • 5.3.2.5. Others
      • 5.3.2.5.1. Others cell Therapy Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million)
    • 5.3.3. Cell Therapy
      • 5.3.3.1. Cell Therapy Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million)

Chapter 6. Cell and Gene Therapy CDMO Market: Indication Estimates & Trend Analysis

  • 6.1. Cell and Gene Therapy CDMO Market, By Indication: Segment Dashboard
  • 6.2. Cell and Gene Therapy CDMO Market, By Indication: Movement Analysis
  • 6.3. Cell and Gene Therapy CDMO Market Estimates & Forecasts, By Indication, 2018 - 2030
    • 6.3.1. Oncology
      • 6.3.1.1. Oncology Cell and Gene Therapy CDMO Market 2018 to 2030 (USD Million)
    • 6.3.2. Infectious Diseases
      • 6.3.2.1. Infectious Diseases Cell and Gene Therapy CDMO Market 2018 to 2030 (USD Million)
    • 6.3.3. Neurological Disorders
      • 6.3.3.1. Neurological Disorders Cell and Gene Therapy CDMO Market 2018 to 2030 (USD Million)
    • 6.3.4. Rare Diseases
      • 6.3.4.1. Rare Diseases Cell and Gene Therapy CDMO Market 2018 to 2030 (USD Million)
    • 6.3.5. Others
      • 6.3.5.1. Others Cell and Gene Therapy CDMO Market 2018 to 2030 (USD Million)

Chapter 7. Cell and Gene Therapy CDMO Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. North America
    • 7.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030
  • 7.5. Europe
    • 7.5.1. UK
      • 7.5.1.1. Key Country Dynamics
      • 7.5.1.2. Competitive Scenario
      • 7.5.1.3. Regulatory Framework
      • 7.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030
    • 7.5.2. Germany
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030
    • 7.5.3. France
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. France Market Estimates and Forecasts, 2018 - 2030
    • 7.5.4. Italy
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030
    • 7.5.5. Spain
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030
    • 7.5.6. Denmark
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Denmark Market Estimates and Forecasts, 2018 - 2030
    • 7.5.7. Sweden
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030
    • 7.5.8. Norway
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Competitive Scenario
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Norway Market Estimates and Forecasts, 2018 - 2030
  • 7.6. Asia Pacific
    • 7.6.1. Japan
      • 7.6.1.1. Key Country Dynamics
      • 7.6.1.2. Competitive Scenario
      • 7.6.1.3. Regulatory Framework
      • 7.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030
    • 7.6.2. India
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. India Market Estimates and Forecasts, 2018 - 2030
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. China Market Estimates and Forecasts, 2018 - 2030
    • 7.6.4. South Korea
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030
    • 7.6.6. Thailand
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Competitive Scenario
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030
  • 7.7. Latin America
    • 7.7.1. Brazil
      • 7.7.1.1. Key Country Dynamics
      • 7.7.1.2. Competitive Scenario
      • 7.7.1.3. Regulatory Framework
      • 7.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030
    • 7.7.2. Mexico
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Mexico Market Estimates and Forecasts, 2018 - 2030
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030
  • 7.8. MEA
    • 7.8.1. South Africa
      • 7.8.1.1. Key Country Dynamics
      • 7.8.1.2. Competitive Scenario
      • 7.8.1.3. Regulatory Framework
      • 7.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030
    • 7.8.2. Saudi Arabia
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Competitive Scenario
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
    • 7.8.3. UAE
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Competitive Scenario
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030
    • 7.8.4. Kuwait
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Competitive Scenario
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Kuwait Market Estimates and Forecasts, 2018 - 2030

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
    • 8.1.1. Innovators
    • 8.1.2. Market Leaders
    • 8.1.3. Emerging Players
    • 8.1.4. Company Market Share Analysis, 2023
  • 8.2. Company Profiles
    • 8.2.1. Lonza
      • 8.2.1.1. Company Overview
      • 8.2.1.2. Financial Performance
      • 8.2.1.3. Service Benchmarking
      • 8.2.1.4. Strategic Initiatives
    • 8.2.2. Catalent, Inc
      • 8.2.2.1. Company Overview
      • 8.2.2.2. Financial Performance
      • 8.2.2.3. Service Benchmarking
      • 8.2.2.4. Strategic Initiatives
    • 8.2.3. Cytiva
      • 8.2.3.1. Company Overview
      • 8.2.3.2. Financial Performance
      • 8.2.3.3. Service Benchmarking
      • 8.2.3.4. Strategic Initiatives
    • 8.2.4. Samsung Biologics
      • 8.2.4.1. Company Overview
      • 8.2.4.2. Financial Performance
      • 8.2.4.3. Service Benchmarking
      • 8.2.4.4. Strategic Initiatives
    • 8.2.5. Thermo Fisher Scientific Inc.
      • 8.2.5.1. Company Overview
      • 8.2.5.2. Financial Performance
      • 8.2.5.3. Service Benchmarking
      • 8.2.5.4. Strategic Initiatives
    • 8.2.6. Novartis AG
      • 8.2.6.1. Company Overview
      • 8.2.6.2. Financial Performance
      • 8.2.6.3. Service Benchmarking
      • 8.2.6.4. Strategic Initiatives
    • 8.2.7. WuXi AppTec
      • 8.2.7.1. Company Overview
      • 8.2.7.2. Financial Performance
      • 8.2.7.3. Service Benchmarking
      • 8.2.7.4. Strategic Initiatives
    • 8.2.8. AGC Biologics
      • 8.2.8.1. Company Overview
      • 8.2.8.2. Financial Performance
      • 8.2.8.3. Service Benchmarking
      • 8.2.8.4. Strategic Initiatives
    • 8.2.9. OmniaBio
      • 8.2.9.1. Company Overview
      • 8.2.9.2. Financial Performance
      • 8.2.9.3. Service Benchmarking
      • 8.2.9.4. Strategic Initiatives
    • 8.2.10. Rentschler Biopharma SE
      • 8.2.10.1. Company Overview
      • 8.2.10.2. Financial Performance
      • 8.2.10.3. Service Benchmarking
      • 8.2.10.4. Strategic Initiatives
    • 8.2.11. Charles River Laboratories
      • 8.2.11.1. Company Overview
      • 8.2.11.2. Financial Performance
      • 8.2.11.3. Service Benchmarking
      • 8.2.11.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviations
  • Table 3 North America Cell and Gene Therapy CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 4 North America Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 5 North America Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 6 North America Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 7 North America Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 8 North America Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 9 U.S. Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 10 U.S. Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 11 U.S. Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 12 U.S. Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 13 U.S. Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 14 Canada Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 15 Canada Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 16 Canada Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 17 Canada Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 18 Canada Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 19 Europe Cell and Gene Therapy CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 20 Europe Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 21 Europe Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 22 Europe Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 23 Europe Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 24 Europe Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 25 UK Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 26 UK Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 27 UK Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 28 UK Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 29 UK Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 30 Germany Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 31 Germany Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 32 Germany Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 33 Germany Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 34 Germany Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 35 France Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 36 France Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 37 France Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 38 France Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 39 France Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 40 Italy Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 41 Italy Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 42 Italy Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 43 Italy Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 44 Italy Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 45 Spain Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 46 Spain Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 47 Spain Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 48 Spain Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 49 Spain Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 50 Denmark Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 51 Denmark Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 52 Denmark Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 53 Denmark Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 54 Denmark Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 55 Sweden Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 56 Sweden Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 57 Sweden Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 58 Sweden Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 59 Sweden Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 60 Norway Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 61 Norway Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 62 Norway Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 63 Norway Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 64 Norway Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 65 Asia Pacific Cell and Gene Therapy CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 66 Asia Pacific Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 67 Asia Pacific Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 68 Asia Pacific Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 69 Asia Pacific Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 70 Asia Pacific Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 71 China Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 72 China Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 73 China Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 74 China Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 75 China Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 76 Japan Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 77 Japan Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 78 Japan Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 79 Japan Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 80 Japan Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 81 India Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 82 India Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 83 India Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 84 India Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 85 India Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 86 Australia Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 87 Australia Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 88 Australia Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 89 Australia Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 90 Australia Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 91 South Korea Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 92 South Korea Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 93 South Korea Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 94 South Korea Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 95 South Korea Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 96 Thailand Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 97 Thailand Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 98 Thailand Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 99 Thailand Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 100 Thailand Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 101 Latin America Cell and Gene Therapy CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 102 Latin America Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 103 Latin America Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 104 Latin America Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 105 Latin America Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 106 Latin America Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 107 Brazil Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 108 Brazil Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 109 Brazil Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 110 Brazil Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 111 Brazil Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 112 Mexico Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 113 Mexico Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 114 Mexico Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 115 Mexico Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 116 Mexico Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 117 Argentina Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 118 Argentina Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 119 Argentina Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 120 Argentina Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 121 Argentina Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 122 Middle East and Africa Cell and Gene Therapy CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 123 Middle East and Africa Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 124 Middle East and Africa Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 125 Middle East and Africa Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 126 Middle East and Africa Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 127 Middle East and Africa Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 128 South Africa Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 129 South Africa Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 130 South Africa Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 131 South Africa Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 132 South Africa Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 133 Saudi Arabia Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 134 Saudi Arabia Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 135 Saudi Arabia Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 136 Saudi Arabia Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 137 Saudi Arabia Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 138 UAE Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 139 UAE Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 140 UAE Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 141 UAE Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 142 UAE Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)
  • Table 143 Kuwait Cell and Gene Therapy CDMO market, by Product Type, 2018 - 2030 (USD Million)
  • Table 144 Kuwait Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
  • Table 145 Kuwait Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 - 2030 (USD Million)
  • Table 146 Kuwait Cell and Gene Therapy CDMO market, by Phase, 2018 - 2030 (USD Million)
  • Table 147 Kuwait Cell and Gene Therapy CDMO market, by Indication, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market research approaches
  • Fig. 4 QFD modeling for market share assessment
  • Fig. 5 Market formulation & validation
  • Fig. 6 Commodity flow analysis
  • Fig. 7 Primary research pattern
  • Fig. 8 Primary interviews in North America
  • Fig. 9 Primary Interviews in Europe
  • Fig. 10 Primary interviews in Asia Pacific
  • Fig. 11 Primary interviews in Latin America
  • Fig. 12 Primary interviews in MEA
  • Fig. 13 Market Snapshot
  • Fig. 14 Segment Snapshot
  • Fig. 15 Segment Snapshot
  • Fig. 16 Competitive Landscape Snapshot
  • Fig. 17 Cell and Gene Therapy CDMO market segmentation
  • Fig. 18 Parent market outlook (2023)
  • Fig. 19 Related/ancillary market outlook (2023)
  • Fig. 20 Market driver relevance analysis (Current & future impact)
  • Fig. 21 Market restraint relevance analysis (Current & future impact)
  • Fig. 22 Porter's Five Forces analysis
  • Fig. 23 SWOT analysis, by a factor (political & legal, economic and technological)
  • Fig. 24 Cell and Gene Therapy CDMO Market Phase Outlook: Segment dashboard
  • Fig. 25 Cell and Gene Therapy CDMO: Phase movement analysis
  • Fig. 26 Pre-clinical market, 2018 - 2030 (USD Million)
  • Fig. 27 Clinical market, 2018 - 2030 (USD Million)
  • Fig. 28 Cell and Gene Therapy CDMO Market Product Type Outlook: Segment dashboard
  • Fig. 29 Cell and Gene Therapy CDMO: Product Type type movement analysis
  • Fig. 30 Gene Therapy market, 2018 - 2030 (USD Million)
  • Fig. 31 Ex-vivo market, 2018 - 2030 (USD Million)
  • Fig. 32 In-vivo market, 2018 - 2030 (USD Million)
  • Fig. 33 Gene-Modified Cell Therapy market, 2018 - 2030 (USD Million)
  • Fig. 34 CAR T-cell therapies market, 2018 - 2030 (USD Million)
  • Fig. 35 CAR-NK cell therapy market, 2018 - 2030 (USD Million)
  • Fig. 36 TCR-T cell therapy market, 2018 - 2030 (USD Million)
  • Fig. 37 Other market, 2018 - 2030 (USD Million)
  • Fig. 38 Cell Therapy market, 2018 - 2030 (USD Million)
  • Fig. 39 Cell and Gene Therapy CDMO market Indication outlook: Segment dashboard
  • Fig. 40 Cell and Gene Therapy CDMO market: Indication movement analysis
  • Fig. 41 Oncology market, 2018 - 2030 (USD Million)
  • Fig. 42 Infectious Diseases market, 2018 - 2030 (USD Million)
  • Fig. 43 Neurological Disorders market, 2018 - 2030 (USD Million)
  • Fig. 44 Rare Diseases market, 2018 - 2030 (USD Million)
  • Fig. 45 Others market, 2018 - 2030 (USD Million)
  • Fig. 46 Regional marketplace: Segment dashboard
  • Fig. 47 Regional outlook, 2023 & 2030
  • Fig. 48 North America market, 2018 - 2030 (USD Million)
  • Fig. 49 U.S. market, 2018 - 2030 (USD Million)
  • Fig. 50 Canada market, 2018 - 2030 (USD Million)
  • Fig. 51 Europe market, 2018 - 2030 (USD Million)
  • Fig. 52 Germany market, 2018 - 2030 (USD Million)
  • Fig. 53 UK market, 2018 - 2030 (USD Million)
  • Fig. 54 France market, 2018 - 2030 (USD Million)
  • Fig. 55 Italy market, 2018 - 2030 (USD Million)
  • Fig. 56 Spain market, 2018 - 2030 (USD Million)
  • Fig. 57 Denmark market, 2018 - 2030(USD Million)
  • Fig. 58 Sweden market, 2018 - 2030 (USD Million)
  • Fig. 59 Norway market, 2018 - 2030 (USD Million)
  • Fig. 60 Asia Pacific market, 2018 - 2030 (USD Million)
  • Fig. 61 China market, 2018 - 2030 (USD Million)
  • Fig. 62 Japan market, 2018 - 2030 (USD Million)
  • Fig. 63 India market, 2018 - 2030 (USD Million)
  • Fig. 64 Australia market, 2018 - 2030 (USD Million)
  • Fig. 65 South Korea market, 2018 - 2030 (USD Million)
  • Fig. 66 Thailand market, 2018 - 2030 (USD Million)
  • Fig. 67 Latin America market, 2018 - 2030 (USD Million)
  • Fig. 68 Brazil market, 2018 - 2030 (USD Million)
  • Fig. 69 Mexico market, 2018 - 2030 (USD Million)
  • Fig. 70 Argentina market, 2018 - 2030 (USD Million)
  • Fig. 71 Middle East & Africa market, 2018 - 2030 (USD Million)
  • Fig. 72 South Africa market, 2018 - 2030 (USD Million)
  • Fig. 73 Saudi Arabia market, 2018 - 2030 (USD Million)
  • Fig. 74 UAE market, 2018 - 2030 (USD Million)
  • Fig. 75 Kuwait market, 2018 - 2030 (USD Million)